studies

la/mBC - HR-positive - 2nd line (L2), HDAC inhibitor vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsE2112, 2021 0.99 [0.81; 1.20] 0.99[0.81; 1.20]E2112, 202110%608NAnot evaluable progression or deaths (PFS)detailed resultsACE, 2019 0.75 [0.58; 0.97] E2112, 2021 0.87 [0.67; 1.13] 0.81[0.67; 0.97]ACE, 2019, E2112, 202120%973lownot evaluable CBRdetailed resultsACE, 2019 1.59 [1.02; 2.49] 1.59[1.02; 2.49]ACE, 201910%365NAnot evaluable DORdetailed resultsACE, 2019 1.43 [0.41; 4.96] 1.43[0.41; 4.96]ACE, 201910%56NAnot evaluable objective responses (ORR)detailed resultsACE, 2019 2.26 [1.12; 4.55] E2112, 2021 1.06 [0.53; 2.09] 1.54[0.73; 3.25]ACE, 2019, E2112, 2021257%973lownot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-01 04:49 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 1364,1374,1365,1366

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons